Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study

References

• ArseneaultLMoffittTECaspiATaylorPJSilvaPAMental disorders and violence in a total birth cohort – results from the Dunedin studyArch Gen Psychiatry2000571097998611015816
   PubMed Web of Science ®Google Scholar
• SeroczynskiADBergemanCSCoccaroEFEtiology of the impulsivity/aggression relationship: genes or environment?Psychiatry Res1999861415710359481
   PubMed Web of Science ®Google Scholar
• ApterAPlutchikRvan PraagHMAnxiety, impulsivity and depressed mood in relation to suicidal and violent behaviorActa Psychiatr Scand1993871158424318
   PubMed Web of Science ®Google Scholar
• ComaiSTauMGobbiGThe psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiologyJ Clin Psychopharmacol2012321839422198449
   PubMed Web of Science ®Google Scholar
• NelsonRJChiavegattoSMolecular basis of aggressionTrends Neurosci2001241271371911718876
   PubMed Web of Science ®Google Scholar
• GobbiGDebonnelGWhat is a recommended treatment for aggression in a patient with schizophrenia?J Psychiatry Neurosci200328432032012921225
   PubMed Web of Science ®Google Scholar
• LeeRCoccaroEThe neuropsychopharmacology of criminality and aggressionCan J Psychiatry2001461354411221488
   PubMed Web of Science ®Google Scholar
• AsbergMTräskmanLThorénP5-HIAA in cerebrospinal fluid. A biochemical suicide predictor?Arch Gen Psychiatry1976331011931197971028
   PubMed Web of Science ®Google Scholar
• BrownGLGoodwinFKBallengerJCGoyerPFMajorLFAggression in humans correlates with cerebrospinal fluid amine metabolitesPsychiatry Res19791213113995232
   PubMed Web of Science ®Google Scholar
• LinnoilaMVirkkunenMScheininMNuutilaARimonRGoodwinFKLow cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behaviorLife Sci19833326260926146198573
   PubMed Web of Science ®Google Scholar
• VirkkunenMGoldmanDNielsenDALinnoilaMLow brain serotonin turnover rate (low CSF 5-HIAA) and impulsive violenceJ Psychiatry Neurosci19952042712757544158
   PubMed Web of Science ®Google Scholar
• CremniterDJamainSKollenbachKCSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjectsBiol Psychiatry199945121572157910376117
   PubMed Web of Science ®Google Scholar
• RoggenbachJMuller-OerlinghausenBFrankeLSuicidality, impulsivity and aggression – is there a link to 5HIAA concentration in the cerebrospinal fluid?Psychiatry Res20021131–219320612467958
   PubMed Web of Science ®Google Scholar
• CleareAJBondAJThe effect of tryptophan depletion and enhancement on subjective and behavioral aggression in normal-male subjectsPsychopharmacology1995118172817597125
   PubMed Web of Science ®Google Scholar
• LeMarquandDGBenkelfatCPihlROPalmourRMYoungSNBehavioral disinhibition induced by tryptophan depletion in nonalcoholic young men with multigenerational family histories of paternal alcoholismAm J Psychiatry1999156111771177910553742
   PubMed Web of Science ®Google Scholar
• LeMarquandDGPihlROYoungSNTryptophan depletion, executive functions, and disinhibition in aggressive, adolescent malesNeuropsychopharmacology19981943333419718596
   PubMed Web of Science ®Google Scholar
• RogersRDBlackshawAJMiddletonHCTryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviourPsychopharmacology1999146448249110550499
   PubMed Web of Science ®Google Scholar
• BellusSBStewartDKostPPClozapine in aggressionPsychiatr Serv19954621871877712263
   PubMed Web of Science ®Google Scholar
• BuckleyPBartellJDonenwirthKLeeSTorigoeFSchulzSCViolence and schizophrenia: clozapine as a specific antiaggressive agentBull Am Acad Psychiatry Law19952346076118639988
   PubMedGoogle Scholar
• ChengappaKNREbelingTKangJSLevineJParepallyHClozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorderJ Clin Psychiatry199960747748410453803
   PubMed Web of Science ®Google Scholar
• FavaMPsychopharmacologic treatment of pathologic aggressionPsychiatr Clin North Am19972024274519196923
   PubMed Web of Science ®Google Scholar
• GlazerWMDicksonRAClozapine reduces violence and persistent aggression in schizophreniaJ Clin Psychiatry1998598149541332
   PubMed Web of Science ®Google Scholar
• PabisDJStanislavSWPharmacotherapy of aggressive behaviorAnn Pharmacother19963032782878833564
   PubMed Web of Science ®Google Scholar
• RabinowitzJAvnonMEffect of clozapine on physical and verbal aggressionSchizophr Res1996182–32492559000322
   PubMed Web of Science ®Google Scholar
• RateyJJLeveroniCKilmerDGutheilCSwartzBThe effects of clozapine on severely aggressive psychiatric inpatients in a state hospitalJ Clin Psychiatry19935462192238331090
   PubMed Web of Science ®Google Scholar
• SpivakBMesterRWittenbergNMamanZWeizmanAReduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patientsClin Neuropharmacol19972054424469331521
   PubMed Web of Science ®Google Scholar
• VolavkaJZitoJMVitraiJCzoborPClozapine effects on hostility and aggression in schizophreniaJ Clin Psychopharmacol19931342872898376618
   PubMed Web of Science ®Google Scholar
• WilsonWHClinical review of clozapine treatment in a state hospitalHosp Community Psychiatry19924377007031516900
   PubMedGoogle Scholar
• AlvirJMJLiebermanJASaffermanAZSchwimmerJLSchaafJAClozapine-induced agranulocytosis. Incidence and risk-factors in the United StatesN Engl J Med199332931621678515788
   PubMed Web of Science ®Google Scholar
• BymasterFPCalligaroDOFalconeJFRadioreceptor binding profile of the atypical antipsychotic olanzapineNeuropsychopharmacology199614287968822531
   PubMed Web of Science ®Google Scholar
• FultonBGoaKLOlanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosesDrugs19975322812989028746
   PubMed Web of Science ®Google Scholar
• KinonBJStaufferVLKollack-WalkerSChenLSniadeckiJOlanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophreniaJ Clin Psychopharmacol200828660160719011427
   PubMed Web of Science ®Google Scholar
• KrakowskiMICzoborPCitromeLBarkNCooperTBAtypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorderArch Gen Psychiatry200663662262916754835
   PubMed Web of Science ®Google Scholar
• StrousRDKupchikMRoitmanSComparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational studyHum Psychopharmacol200621423524316783815
   PubMed Web of Science ®Google Scholar
• VolavkaJCzoborPNolanKOvert aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidolJ Clin Psychopharmacol200424222522815206671
   PubMed Web of Science ®Google Scholar
• Newman-TancrediAGavaudanSConteCAgonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [S-35] GTPgammaS binding studyEur J Pharmacol19983552–32452569760039
   PubMed Web of Science ®Google Scholar
• TysonPJRobertsKHMortimerAMAre the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?Int J Neurosci2004114659361115204055
   PubMed Web of Science ®Google Scholar
• RauserLSavageJEMeltzerHYRothBLInverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptorJ Pharmacol Exp Ther20012991838911561066
   PubMed Web of Science ®Google Scholar
• ArangoCBernardoMThe effect of quetiapine on aggression and hostility in patients with schizophreniaHum Psychopharmol2005204237241
   Web of Science ®Google Scholar
• CantillonMGoldsteinJMQuetiapine fumarate reduces aggression and hostility in patients with schizophreniaPoster presented at: American Psychiatric Association 151st Annual MeetingMay 30–June 4, 1998Toronto, Canada
   Google Scholar
• ChengappaKNGoldsteinJMGreenwoodMJohnVLevineJA post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophreniaClin Ther200325253054112749512
   PubMed Web of Science ®Google Scholar
• KalaliASchulzSCKahnRSEffectiveness of once-daily extended release quetiapine fumarate (quetiapine xr) for excitability, hostility and aggression in schizophreniaSchizophr Res200898Suppl 1164
   Google Scholar
• VillariVRoccaPFonzoVMontemagniCPandulloPBogettoFOral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitationProg Neuropsychopharmacol Biol Psychiatry200832240541317900775
   PubMed Web of Science ®Google Scholar
• BitterICzoborPDossenbachMVolavkaJEffectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)Eur Psychiatry2005205–640340816084068
   PubMed Web of Science ®Google Scholar
• SwansonJWSwartzMSVan DornRAComparison of antipsychotic medication effects on reducing violence in people with schizophreniaBr J Psychiatry20081931374318700216
   PubMed Web of Science ®Google Scholar
• FoleySRKellyBDClarkeMIncidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosisSchizophr Res2005722–316116815560961
   PubMed Web of Science ®Google Scholar
• LecrubierYBraconnierASaidSPayanCThe impulsivity rating scale (IRS): preliminary resultsEur Psychiatry199510733133819698364
   PubMed Web of Science ®Google Scholar
• OverallJE GDThe brief psychiatric rating scalePsychol Rep196210799812
   Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology – Revised, 1976Rockville, MAUS Department of Health, Education, and Welfare1976218222
   Google Scholar
• StreinerD GJIntention to treat analysis in clinical trials when there are missing dataEvid Based Ment Health20014707112004740
   PubMedGoogle Scholar
• BreierAMeehanKBirkettMA double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophreniaArch Gen Psychiatry200259544144811982448
   PubMed Web of Science ®Google Scholar
• LambertMHuberCGNaberDTreatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorderPharmacopsychiatry200841518218918763220
   PubMed Web of Science ®Google Scholar
• SanLArranzBQuerejetaIBarrioSDe la GandaraJPerezVA naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patientsEur Psychiatry200621853954316697151
   PubMed Web of Science ®Google Scholar
• WangXSavageRBorisovAEfficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch studyJ Psychiatr Res200640766967616762371
   PubMed Web of Science ®Google Scholar
• WrightPBirkettMDavidSRDouble-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophreniaAm J Psychiatry200115871149115111431240
   PubMed Web of Science ®Google Scholar
• GanesanSLevyMBilskerDKhanbhaiIEffectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trialInt J Psychiatry Clin Pract200593199203
   PubMed Web of Science ®Google Scholar
• KimEBijlaniMA pilot study of quetiapine treatment of aggression due to traumatic brain injuryJ Neuropsychiatry Clin Neurosci200618454754917135382
   PubMed Web of Science ®Google Scholar
• KronenbergerWGGiauqueALLafataDEBohnstedtBNMaxeyLEDunnDWQuetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label studyJ Child Adolesc Psychopharmacol200717333434717630867
   PubMed Web of Science ®Google Scholar
• DaweGSHuffKDVandergriffJLSharpTO’NeillMJRasmussenKOlanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivityBiol Psychiatry200150751052011600104
   PubMed Web of Science ®Google Scholar
• BlierPSzaboSTPotential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxietyJ Clin Psychiatry200566Suppl 8304016336034
   PubMed Web of Science ®Google Scholar
• CalabreseJRKeckPEJrMacfaddenWA randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depressionAm J Psychiatry200516271351136015994719
   PubMed Web of Science ®Google Scholar
• AtmacaMKulogluMTezcanEGeciciOUstundagBWeight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidolSchizophr Res20036019910012505146
   PubMed Web of Science ®Google Scholar